8 research outputs found
Oxidative stress as an important contributor to the pathogenesis of psoriasis
This review discusses how oxidative stress (OS), an imbalance between oxidants and antioxidants in favor of the oxidants, increased production of reactive oxygen species (ROS)/reactive nitrogen species (RNS), and decreased concentration/activity of antioxidants affect the pathogenesis or cause the enhancement of psoriasis (Ps). Here, we also consider how ROS/RNS-induced stress modulates the activity of transcriptional factors and regulates numerous protein kinase cascades that participate in the regulation of crosstalk between autophagy, apoptosis, and regeneration. Answers to these questions will likely uncover novel strategies for the treatment of Ps. Action in the field will avoid destructive effects of ROS/RNS-mediated OS resulting in cellular dysfunction and cell death. The combination of the fragmentary information on the role of OS can provide evidence to extend the full picture of Ps
Nonsteroidal anti-inflammatory drugs modulate cellular glycosaminoglycan synthesis by affecting EGFR and PI3K signaling pathways
In this report, selected non-steroidal anti-inflammatory drugs (NSAIDs), indomethacin and nimesulide,
and analgesics acetaminophen, alone, as well as in combination with isoflavone genistein as
potential glycosaminoglycan (GAG) metabolism modulators were considered for the treatment of
mucopolysaccharidoses (MPSs) with neurological symptoms due to the effective blood-brain barrier\ud
(BBB) penetration properties of these compounds. We found that indomethacin and nimesulide, but
not acetaminophen, inhibited GAG synthesis in fibroblasts significantly, while the most pronounced
impairment of glycosaminoglycan production was observed after exposure to the mixture of nimesulide
and genistein. Phosphorylation of the EGF receptor (EGFR) was inhibited even more effective in the
presence of indomethacin and nimesulide than in the presence of genistein. When examined the
activity of phosphatidylinositol-3-kinase (PI3K) production, we observed its most significant decrease
in the case of fibroblast exposition to nimesulide, and afterwards to indomethacin and genistein mix,
rather than indomethacin used alone. Some effects on expression of individual GAG metabolism-related
and lysosomal function genes, and significant activity modulation of a number of genes involved in
intracellular signal transduction pathways and metabolism of DNA and proteins were detected. This
study documents that NSAIDs, and their mixtures with genistein modulate cellular glycosaminoglycan
synthesis by affecting EGFR and PI3K signaling pathways
Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids
Flavonoids were found previously to modulate efficiency of synthesis of glycosaminoglycans (GAGs),
compounds which are accumulated in cells of patients suffering from mucopolysaccharidoses (MPSs). The
aim of this work was to determine effects of different flavonoids (genistein, kaempferol, daidzein) used alone
or in combinations, on expression of genes coding for proteins involved in GAG metabolism. Analyses with
DNA microarray, followed by real-time qRT-PCR revealed that genistein, kaempferol and combination of
these two compounds induced dose- and time-dependent remarkable alterations in transcript profiles of
GAG metabolism genes in cultures of wild-type human dermal fibroblasts (HDFa). Interestingly, effects of
the mixture of genistein and kaempferol were stronger than those revealed by any of these compounds used
alone. Similarly, the most effective reduction in levels of GAG production, in both HDFa and MPS II cells, was observed in the presence of genistein, keampferol and combination of these compounds. Forty five genes were chosen for further verification not only in HDFa, but also inMPS II fibroblasts by using real-time qRT-PCR. Despite effects on GAG metabolism-related genes, we found that genistein, kaempferol and mixture of these compounds significantly stimulated expression of TFEB. Additionally, a decrease inMTOR transcript level was observed at these conditions
Non-steroidal anti-inflammatory drugs are safe with respect to the transcriptome of human dermal fibroblasts
Non-steroidal anti-inflammatory drugs (NSAIDs) provide important benefits to millions of patients, but are associated
with a number of serious adverse events. These adverse drug reactions are an important clinical issue
and a serious public health risk. While most unfortunate responses in human to NSAIDs are mild and may
disappear after decreasing the dose or withdrawal of the drug, some of them can produce serious outcomes.
Currently, little is known regarding the effects of NSAIDs on global RNA expression in normal, non-transformed
cells. Therefore, in this report, the effect of NSAIDs, COX-nonspecific and COX-2-specific inhibitors, indomethacin
and nimesulide respectively, commonly used medications worldwide for the reduction of pain,
fever, inflammation and stiffness, on transcriptomic signature of human dermal fibroblasts was investigated. A
total of 3803 differentially expressed genes with a fold change greater than or equal to 1.3 and below than or
equal to 0.7 for whole genome transcripts, with a P value of<0.05 were identified in response to all applied
conditions. We found that although the total number of deregulated genes was relatively high at such criteria,
changes in fibroblast transcriptome profile after treatment at selected experimental conditions were however
smallish, as the selected drugs slightly modulate transcriptome with only a few genes with expression altered a
bit more than twice. Nevertheless, transcriptomic data has its own limitations and it cannot reflect all posttranscriptional
changes, which in turn may cause same risks, especially for a long time of medication
Differential RNA editing landscapes in host cell versus the SARS-CoV-2 genome
: The SARS-CoV-2 pandemic was defined by the emergence of new variants formed through virus mutation originating from random errors not corrected by viral proofreading and/or the host antiviral response introducing mutations into the viral genome. While sequencing information hints at cellular RNA editing pathways playing a role in viral evolution, here, we use an in vitro human cell infection model to assess RNA mutation types in two SARS-CoV-2 strains representing the original and the alpha variants. The variants showed both different cellular responses and mutation patterns with alpha showing higher mutation frequency with most substitutions observed being C-U, indicating an important role for apolipoprotein B mRNA editing catalytic polypeptide-like editing. Knockdown of select APOBEC3s through RNAi increased virus production in the original virus, but not in alpha. Overall, these data suggest a deaminase-independent anti-viral function of APOBECs in SARS-CoV-2 while the C-U editing itself might function to enhance genetic diversity enabling evolutionary adaptation
The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activation
Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) has been previously proposed as a potential drug for use in substrate reduction therapy for mucopolysaccharidoses, a group of inherited metabolic diseases caused by mutations leading to inefficient degradation of glycosaminoglycans (GAGs) in lysosomes. It was demonstrated that this isoflavone can cross the blood-brain barrier, making it an especially desirable potential drug for the treatment of neurological symptoms present in most lysosomal storage diseases. So far, no comprehensive genomic analyses have been performed to elucidate the molecular mechanisms underlying the effect elicited by genistein. Therefore, the aim of this work was to identify the genistein-modulated gene network regulating GAG biosynthesis and degradation, taking into consideration the entire lysosomal metabolism. Our analyses identified over 60 genes with known roles in lysosomal biogenesis and/or function whose expression was enhanced by genistein. Moreover, 19 genes whose products are involved in both GAG synthesis and degradation pathways were found to be remarkably differentially regulated by genistein treatment. We found a regulatory network linking genistein- mediated control of transcription factor EB (TFEB) gene expression, TFEB nuclear translocation, and activation of TFEB-dependent lysosome biogenesis to lysosomal metabolism. Our data indicate that the molecular mechanism of genistein action involves not only impairment of GAG synthesis but more importantly lysosomal enhancement via TFEB. These findings contribute to explaining the beneficial effects of genistein in lysosomal storage diseases as well as envisage new therapeutic approaches to treat these devastating diseases